Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
Go back to Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 103.40 +5.18 (5.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $98.22 | 52 Week High | $118.49 | |||
| Open | $99.79 | 52 Week Low | $55.00 | |||
| Day High | $103.40 | P/E | N/A | |||
| Day Low | $99.79 | EPS | $-0.56 | |||
| Volume | 819,769 | |||||
